=Amarin (AMRN) : Diabetes Association Adds Drug to Its 'Must Have' List

• Amarin Corporation plc (AMRN) confirmed that the American Diabetes Association (ADA) issued important updates to the Standards of Medical Care in Diabetes for 2019 (Standards of Care), including updates related to the results of the REDUCE-IT cardiovascular outcomes study.

The company's Vascepa drug was added to the American Diabetes Association's Standards of Medical Care in Diabetes list for 2019. 

The drug, along with a specialized diet, has been shown to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Amarin has agreed to give the Food and Drug Administration data to support the ADA's finding in order expand Vascepa's FDA label to include its recommendation. 

"As we have commenced transmission of data to the FDA for the submission of our sNDA seeking an expansion of the Vascepa label based on the landmark REDUCE-IT results, we are pleased by ADA's acknowledgement of the importance of the REDUCE-IT results in its 2019 update of the Standards of Care," said Dr. Craig B. Granowitz, senior vice president and chief medical officer of Amarin.

Amarin said that Vascepa works without raising bad cholesterol when a four-gram dose is taken daily.